Skip to main content

Clinical Approach to ARVC

 


Clinical Approach to ARVC

✅ECG features of Arrhythmogenic Right Ventricular Dysplasia (ARVD) with:

πŸ”Ή TWI in precordial leads, in absence of RBBB.

πŸ”Ή Epsilon wave (most specific finding).

πŸ”Ή Localised widened QRS in V1-V3 (due to delayed RV activation).


ARVD:

- Genetic disorder of fibrofatty infiltration of myocardium. 


- Most common symptoms are palpitations/ syncope during exercise. 


- VT with LBBB pattern can become VF, usually triggered by adrenergic stimulation (e.g. exercise).




Arrhythmogenic Right Ventricular Dysplasia (ARVD), also termed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), is an inherited myocardial disease characterized by progressive fibrofatty replacement of right ventricular myocardium, leading to ventricular arrhythmias and sudden cardiac death, particularly in young individuals and athletes.



---


Definition and Pathophysiology


ARVD is a genetic cardiomyopathy, most commonly inherited in an autosomal dominant pattern. It primarily involves mutations in desmosomal proteins (plakophilin-2, desmoglein-2, desmocollin-2, desmoplakin), resulting in impaired cell-to-cell adhesion.


Loss of myocardial integrity leads to:


Myocyte detachment


Cell death


Replacement with fibrofatty tissue

This process predominantly affects the right ventricle, especially the inflow tract, outflow tract, and apex (“triangle of dysplasia”), causing delayed conduction and arrhythmogenesis.




---


ECG Features of ARVD


Electrocardiogram abnormalities are central to diagnosis and often precede structural changes.


1. T-Wave Inversion (TWI)


Present in right precordial leads (V1–V3)


Occurs in the absence of complete RBBB


Reflects abnormal repolarization due to RV myocardial disease


More significant in adults (>14 years)



2. Epsilon Wave (Most Specific Finding)


Small, low-amplitude deflection at the end of QRS complex, best seen in V1–V3


Represents delayed activation of diseased RV myocardium


Often subtle and may require signal-averaged ECG or high-gain recording



3. Localized QRS Widening (V1–V3)


QRS duration prolonged in right precordial leads compared with left leads


Caused by slow conduction through fibrofatty RV tissue


Sometimes described as terminal activation delay ≥55 ms



Other ECG Findings


Low QRS voltage


Fragmented QRS complexes


Ventricular ectopics with LBBB morphology




---


Clinical Presentation


ARVD commonly presents in young adults or athletes, often during exertion.


Common Symptoms


Palpitations


Syncope or presyncope (especially during exercise)


Sudden cardiac death as first manifestation in some cases



Ventricular Arrhythmias


Ventricular tachycardia with LBBB morphology (originating from RV)


VT may degenerate into ventricular fibrillation


Arrhythmias are often adrenergically triggered (exercise, emotional stress)




---


Diagnosis


Diagnosis is based on Revised Task Force Criteria, incorporating:


ECG abnormalities


Ventricular arrhythmias


Imaging (echo, cardiac MRI)


Histopathology


Family history and genetics



Cardiac MRI is particularly useful to demonstrate:


RV dilation or dysfunction


Fibrofatty infiltration


Late gadolinium enhancement




---


Management


Lifestyle


Strict avoidance of competitive sports and strenuous exercise



Medical Therapy


Beta-blockers


Antiarrhythmic drugs (e.g. sotalol, amiodarone)



Device Therapy


Implantable cardioverter-defibrillator (ICD) for:


Sustained VT


Syncope with high-risk features


Survivors of cardiac arrest




Catheter Ablation


For recurrent VT, usually adjunctive, not curative




---


Prognosis


ARVD is a progressive disease with variable expression. Early diagnosis and exercise restriction significantly reduce arrhythmic risk. Sudden cardiac death remains the major cause of mortality, especially in undiagnosed young individuals.



---


Key Takeaway


ARVD should be suspected in young patients with exertional syncope or VT with LBBB morphology. Epsilon waves, T-wave inversion in V1–V3 without RBBB, and localized QRS widening are hallmark ECG clues that should prompt further evaluation.


For more cardiology articles and ECG infographics, visit: drmusmanjaved.com


Comments

Popular posts from this blog

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB)

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB) Why this differentiation matters Brugada pattern is a malignant channelopathy associated with sudden cardiac death, while incomplete RBBB is usually a benign conduction variant. Mislabeling Brugada as iRBBB can be fatal; overcalling iRBBB as Brugada can lead to unnecessary anxiety and ICD implantation. --- 1. Basic Definitions Brugada ECG Pattern Primary repolarization abnormality Genetic sodium-channel disorder Characteristic ST-segment elevation in V1–V3 Risk of ventricular fibrillation and sudden death Incomplete RBBB (iRBBB) Depolarization abnormality Delay in right ventricular conduction Common in healthy individuals Usually asymptomatic and benign --- 2. ECG Morphology: Side-by-Side Comparison QRS Duration Brugada: QRS usually <120 ms iRBBB: QRS <120 ms, but with RBBB morphology --- V1–V2 Pattern (Key Differentiator) Brugada Pseudo-RBBB appearance ST elevation ≥2 mm ST segment is coved or saddleback Terminal QRS bl...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...